ESMO 2025 preview – Astra and Daiichi keep abreast of Gilead
Datroway succeeds on PFS and OS in Tropion-Breast02, and an ESMO showdown beckons.
ESMO 2025 preview – a bemarituzumab reckoning approaches
Meanwhile, Astra, Merck and Novartis look for new Enhertu, Keytruda and Pluvicto additions.
Better late than never for Datroway in lung cancer
Astra/Daiichi have trumped Gilead’s Trodelvy with a lung cancer approval.
Trodelvy gets one up on Datroway in triple-negative breast
Gilead’s TROP2 ADC prevails in Ascent-04, in first-line PD-L1-positive TNBC.
Elevation goes down on Claudin disaster
The honeymoon is over for Claudin18.2, as Elevation drops EO-3021.
Yet more conjugates enter the clinic
Recent phase 1 entrants include a ROR1 ADC and a mystery Kelun project.
Merck gets saci in ovarian
Sacituzumab tirumotecan joins raludotatug deruxtecan on the ovarian cancer pivotal stage.
Conjugates enter their first clinical trials
Two Kelun ADCs and two actinium-based radioconjugates start phase 1.
